What is the appropriate first‑line antipsychotic medication to start for this patient after medical causes have been excluded?

Atypical Antipsychotic as First-Line Treatment

For a patient with psychotic symptoms after medical causes have been ruled out, initiate treatment with a low-dose atypical (second-generation) antipsychotic, specifically risperidone 0.25-2 mg/day, olanzapine 2.5-10 mg/day, or quetiapine 12.5 mg twice daily as starting options.

Rationale for Atypical Antipsychotics

The evidence strongly supports atypical antipsychotics as first-line agents over typical (first-generation) antipsychotics. Atypical agents carry significantly lower risk of extrapyramidal symptoms (EPS) and tardive dyskinesia, which is critical since tardive dyskinesia can develop in 50% of elderly patients after just 2 years of continuous typical antipsychotic use 1. This side effect profile is particularly important for treatment adherence and quality of life.

Specific Medication Recommendations

For Alzheimer's Disease/Dementia-Related Psychosis:

• Risperidone: Start 0.25 mg daily at bedtime; maximum 2-3 mg/day in divided doses. Current research supports low dosages; EPS may occur at ≥2 mg/day 1
• Olanzapine: Start 2.5 mg daily at bedtime; maximum 10 mg/day in divided doses. Generally well tolerated 1
• Quetiapine: Start 12.5 mg twice daily; maximum 200 mg twice daily. More sedating; monitor for orthostatic hypotension 1

For First-Episode Psychosis/Schizophrenia:

The most recent international guidelines 2 recommend collaborative selection based on side-effect profiles, with amisulpride, risperidone, paliperidone, or olanzapine as preferred first-line options. For D2 partial agonists (like aripiprazole), these agents are specifically recommended as second-line 2.

Olanzapine with concurrent metformin should be strongly considered to attenuate metabolic side effects 2. The 2025 INTEGRATE guidelines emphasize starting metformin prophylactically with olanzapine to prevent weight gain.

For Acute Agitation in Emergency Settings:

• Oral combination: Lorazepam 2 mg + risperidone for cooperative patients 3
• Parenteral monotherapy: Haloperidol 5 mg IM or lorazepam 2-4 mg if rapid sedation needed 3
• Ziprasidone 20 mg IM shows excellent efficacy with notably lower EPS rates compared to haloperidol 3

Critical Dosing Principles

Start low and titrate slowly—this is non-negotiable. For first-episode patients, use the lowest effective dose within the therapeutic range 4, 2. Assess response at 4 weeks minimum before declaring treatment failure 2, 5. Increasing doses above therapeutic range lacks evidence and increases side effects 2.

When to Avoid Typical Antipsychotics

Typical antipsychotics should be second-line only, reserved for patients who cannot tolerate or fail atypical agents 1. They carry unacceptable risks of:

• Severe cholinergic, cardiovascular, and extrapyramidal side effects
• 50% risk of irreversible tardive dyskinesia after 2 years in elderly patients 1
• Never use in Parkinson's disease or Lewy body dementia due to severe EPS risk 6

Common Pitfalls to Avoid

1. Don't wait too long to assess response: Evaluate at 4 weeks, not months 2
2. Don't use anticholinergics prophylactically: Only treat EPS if it occurs 1
3. Don't combine benzodiazepines with high-dose olanzapine: Risk of fatal oversedation and respiratory depression 6
4. Don't ignore metabolic monitoring: Start metformin with olanzapine or clozapine from day one 2
5. Don't exceed therapeutic doses without documented plasma levels: More is not better 2

Special Populations

Elderly/frail patients: Use half the standard starting dose (e.g., risperidone 0.25 mg, olanzapine 2.5 mg) and titrate more gradually 6.

Hepatic/renal impairment: Reduce doses accordingly; quetiapine and risperidone require particular caution 6.

Treatment Resistance Algorithm

If symptoms persist after 4 weeks at therapeutic dose with good adherence:

1. Switch to alternative atypical antipsychotic with different receptor profile 2
2. If second agent fails after 4 weeks, reassess diagnosis and rule out substance use, organic causes 2
3. If diagnosis confirmed and two adequate trials failed, initiate clozapine with concurrent metformin 2, 5

The APA guidelines 5 give clozapine a 1B recommendation (strong evidence) for treatment-resistant schizophrenia, making it the only antipsychotic with proven efficacy in this population.